JP2016153424A5 - - Google Patents

Download PDF

Info

Publication number
JP2016153424A5
JP2016153424A5 JP2016097613A JP2016097613A JP2016153424A5 JP 2016153424 A5 JP2016153424 A5 JP 2016153424A5 JP 2016097613 A JP2016097613 A JP 2016097613A JP 2016097613 A JP2016097613 A JP 2016097613A JP 2016153424 A5 JP2016153424 A5 JP 2016153424A5
Authority
JP
Japan
Prior art keywords
dioxol
difluoro
benzo
formula
cyclopropanecarboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016097613A
Other languages
English (en)
Japanese (ja)
Other versions
JP6158985B2 (ja
JP2016153424A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016153424A publication Critical patent/JP2016153424A/ja
Publication of JP2016153424A5 publication Critical patent/JP2016153424A5/ja
Application granted granted Critical
Publication of JP6158985B2 publication Critical patent/JP6158985B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2016097613A 2004-01-30 2016-05-16 Ａｔｐ結合カセットトランスポーターのモジュレーター Expired - Lifetime JP6158985B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54056404P 2004-01-30 2004-01-30
US60/540,564 2004-01-30
US60350304P 2004-08-20 2004-08-20
US60/603,503 2004-08-20

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2015019897A Division JP2015091875A (ja) 2004-01-30 2015-02-04 Ａｔｐ結合カセットトランスポーターのモジュレーター

Publications (3)

Publication Number Publication Date
JP2016153424A JP2016153424A (ja) 2016-08-25
JP2016153424A5 true JP2016153424A5 (https=) 2017-03-30
JP6158985B2 JP6158985B2 (ja) 2017-07-05

Family

ID=34841105

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2006551487A Expired - Lifetime JP4960708B2 (ja) 2004-01-30 2005-01-31 Ａｔｐ結合カセットトランスポーターのモジュレーター
JP2012009781A Expired - Lifetime JP5669319B2 (ja) 2004-01-30 2012-01-20 Ａｔｐ結合カセットトランスポーターのモジュレーター
JP2014021918A Expired - Lifetime JP5840239B2 (ja) 2004-01-30 2014-02-07 Ａｔｐ結合カセットトランスポーターのモジュレーター
JP2015019897A Pending JP2015091875A (ja) 2004-01-30 2015-02-04 Ａｔｐ結合カセットトランスポーターのモジュレーター
JP2016097613A Expired - Lifetime JP6158985B2 (ja) 2004-01-30 2016-05-16 Ａｔｐ結合カセットトランスポーターのモジュレーター

Family Applications Before (4)

Application Number Title Priority Date Filing Date
JP2006551487A Expired - Lifetime JP4960708B2 (ja) 2004-01-30 2005-01-31 Ａｔｐ結合カセットトランスポーターのモジュレーター
JP2012009781A Expired - Lifetime JP5669319B2 (ja) 2004-01-30 2012-01-20 Ａｔｐ結合カセットトランスポーターのモジュレーター
JP2014021918A Expired - Lifetime JP5840239B2 (ja) 2004-01-30 2014-02-07 Ａｔｐ結合カセットトランスポーターのモジュレーター
JP2015019897A Pending JP2015091875A (ja) 2004-01-30 2015-02-04 Ａｔｐ結合カセットトランスポーターのモジュレーター

Country Status (10)

Country Link
US (1) US8759335B2 (https=)
EP (2) EP1716122B1 (https=)
JP (5) JP4960708B2 (https=)
CN (1) CN1938279B (https=)
AU (1) AU2005210474B2 (https=)
BR (1) BRPI0507278A (https=)
CA (1) CA2554796A1 (https=)
ES (2) ES2791303T3 (https=)
MX (1) MXPA06008606A (https=)
WO (1) WO2005075435A1 (https=)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006111093A (ru) 2003-09-06 2007-10-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы атр-связывающих кассетных транспортеров
CN101675928A (zh) * 2003-11-14 2010-03-24 沃泰克斯药物股份有限公司 可用作atp-结合弹夹转运蛋白调控剂的噻唑和噁唑
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
RS56037B1 (sr) 2004-06-24 2017-09-29 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
CA2587667A1 (en) * 2004-11-15 2006-05-18 Taisho Pharmaceutical Co., Ltd. Imine compound
US7999113B2 (en) 2005-08-11 2011-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
KR20080064971A (ko) 2005-10-06 2008-07-10 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ-결합 카세트 전달체의 조절자
CN102775396B (zh) * 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
AU2012201325B2 (en) * 2005-11-08 2012-05-03 Vertex Pharmaceuticals Incorporated Heterocyclic Modulators of ATP-Binding Cassette Transporters
EP3219705B1 (en) 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CA2856037C (en) * 2005-12-28 2017-03-07 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
NZ570103A (en) * 2006-01-26 2011-11-25 Foldrx Pharmaceuticals Inc Compounds and methods for modulating protein trafficking
AU2013205183B2 (en) * 2006-04-07 2016-07-28 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2674428B1 (en) 2006-04-07 2016-04-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) * 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
NZ576642A (en) * 2006-11-03 2011-11-25 Vertex Pharma Azaindole derivatives as cftr modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
DE602008005140D1 (de) 2007-05-07 2011-04-07 Novartis Ag Organische verbindungen
CN104447716A (zh) * 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
CA2687715A1 (en) * 2007-05-09 2008-11-20 Traffick Therapeutics Inc. Screening assay to identify correctors of protein trafficking defects
AU2008256937A1 (en) * 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
WO2009003289A1 (en) * 2007-07-03 2009-01-08 The University Of British Columbia Small molecule correctors of deltaf508 cftr trafficking
RS54303B1 (sr) * 2007-07-19 2016-02-29 Lundbeck, H., A/S 5-člani heterociklični amidi i srodna jedinjenja
JP5389030B2 (ja) 2007-08-24 2014-01-15 バーテックス ファーマシューティカルズ インコーポレイテッド （特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン
AU2013231151B2 (en) * 2007-11-16 2015-06-25 Vertex Pharmaceuticals Incorporated Isoquinoline modulators of ATP-Binding Cassette transporters
SI2578571T1 (sl) 2007-11-16 2016-01-29 Vertex Pharmaceuticals Incorporated Izokinolinski modulatorji prenašalcev z atp-vezavno kaseto
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
MX365732B (es) * 2007-12-07 2019-06-12 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
CN101998854A (zh) * 2007-12-07 2011-03-30 沃泰克斯药物股份有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)环丙烷甲酰氨基)-3-甲基吡啶-2-基)苯甲酸的制剂
MX2010006421A (es) 2007-12-10 2010-06-25 Novartis Ag Compuestos organicos.
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
AU2015228930B2 (en) * 2008-02-28 2017-02-23 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR modulators
AU2013205162B2 (en) * 2008-02-28 2015-07-09 Vertex Pharmaceuticals Incorporated Heteroaryl derivatives as CFTR modulators
NZ616097A (en) * 2008-03-31 2015-04-24 Vertex Pharma Pyridyl derivatives as cftr modulators
AU2013270464B2 (en) * 2008-03-31 2016-05-26 Vertex Pharmaceuticals Incorporated Pyridyl derivatives as CFTR modulators
JP2011522860A (ja) 2008-06-10 2011-08-04 ノバルティス アーゲー 上皮性ナトリウムチャネルブロッカーとしてのピラジン誘導体
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
AR073709A1 (es) 2008-09-29 2010-11-24 Vertex Pharma Unidades de dosis de acido 3-(6-(1-(2,2-difluorobenzeno (d) (1,3) dioxol-5-il) ciclopropancarboxamido)-3-metilpiridin-2-il) benzoico
EP2349263B1 (en) * 2008-10-23 2014-04-23 Vertex Pharmaceuticals Inc. Modulators of cystic fibrosis transmembrane conductance regulator
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
WO2010098428A1 (ja) 2009-02-27 2010-09-02 帝人ファーマ株式会社 遷移金属触媒を用いたカップリング法によるフェニル置換複素環誘導体の製造法
PL2408750T3 (pl) 2009-03-20 2016-02-29 Vertex Pharma Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
MX2012004792A (es) 2009-10-22 2013-02-01 Vertex Pharma Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
WO2011093352A1 (ja) * 2010-01-27 2011-08-04 武田薬品工業株式会社 チアゾール誘導体
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
MX2012011655A (es) 2010-04-07 2012-11-23 Vertex Pharma Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo [d][1-3]dioxol-5-il]ciclopropanocarboxamido)-3-metilpiridin-2-il) benzoico.
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の医薬組成物およびその投与
EP2560649A1 (en) 2010-04-22 2013-02-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
CA2796602A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
EP2560651A1 (en) 2010-04-22 2013-02-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
MX353408B (es) 2010-04-22 2018-01-11 Vertex Pharma Proceso para producir compuestos de cicloalquilcarboxamido-indol.
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
CN103068807B (zh) 2010-08-27 2016-05-25 帝人制药株式会社 通过使用钯化合物的偶合法的苯基取代杂环衍生物的制备方法
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US9073895B2 (en) 2010-12-16 2015-07-07 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
WO2013070961A1 (en) 2011-11-08 2013-05-16 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
TWI640519B (zh) * 2011-11-29 2018-11-11 泰緯生命科技股份有限公司 Ｈｅｃ１活性調控因子及其調節方法
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2013158121A1 (en) 2012-04-20 2013-10-24 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2013270681A1 (en) 2012-06-08 2014-12-18 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of CFTR -mediated disorders
AR092857A1 (es) 2012-07-16 2015-05-06 Vertex Pharma Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
ITMI20122065A1 (it) 2012-12-03 2014-06-04 Univ Padova Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
WO2014180562A1 (en) * 2013-05-07 2014-11-13 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
US9914740B2 (en) 2013-07-02 2018-03-13 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
EP3016950B1 (en) 2013-07-02 2017-06-07 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
EP2878339A1 (en) 2013-12-02 2015-06-03 Siena Biotech S.p.A. SIP3 antagonists
RU2744460C2 (ru) 2014-04-15 2021-03-09 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтические композиции для лечения заболеваний, опосредованных муковисцидозным трансмембранным регулятором проводимости
MA41051B1 (fr) 2014-10-06 2020-11-30 Vertex Pharma Modulateurs du régulateur de conductance transmembranaire de la mucoviscidose
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
DK3212189T3 (da) 2014-10-31 2020-10-26 Abbvie Overseas Sarl Substituerede chromaner og fremgangsmåde til anvendelse deraf
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
CN104693164B (zh) * 2015-03-31 2017-03-08 衢州康鹏化学有限公司 一种 2，2‑二氟胡椒酸甲酯的制备方法
US9840513B2 (en) * 2015-07-16 2017-12-12 Abbvie S.Á.R.L. Substituted tricyclics and method of use
RU2742934C2 (ru) * 2015-12-24 2021-02-11 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Кфтр регуляторы и способы их применения
AU2016379444B2 (en) 2015-12-24 2021-04-29 The Regents Of The University Of California CFTR regulators and methods of use thereof
JP6918823B2 (ja) * 2016-04-06 2021-08-11 イノベーティブ モレキュールズ ゲーエムベーハーＩｎｎｏｖａｔｉｖｅ Ｍｏｌｅｃｕｌｅｓ Ｇｍｂｈ 抗ウイルス剤として有用なアミノチアゾール誘導体
CN109803962B (zh) 2016-09-30 2022-04-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调控蛋白的调节剂、以及药物组合物
WO2018107040A1 (en) * 2016-12-09 2018-06-14 Vertex Pharmaceuticals Incorporated 1-(2-fluorophenyl)-n-[1-(2-fluoro-4-pyridyl)pyrazol-3-yl]cyclopropanecarboxamide, its solid forms and pharmaceutical uses thereof
UY37512A (es) * 2016-12-09 2019-04-30 Vertex Pharma Compuestos pirazol 1,3-sustituido útiles para la reducción de los niveles de ácidos grasos de cadena muy larga
MD3551622T2 (ro) 2016-12-09 2021-03-31 Vertex Pharma Modulator al regulatorului conductanței transmembranare în fibroză chistică, compoziții farmaceutice, metode de tratament și procedeu pentru fabricarea modulatorului
US10968225B2 (en) 2017-03-14 2021-04-06 Fondazione Istituto Italiano Di Tecnologia Compounds and compositions for the treatment of cystic fibrosis
IT201700028127A1 (it) * 2017-03-14 2018-09-14 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento della fibrosi cistica
IT201700028184A1 (it) * 2017-03-14 2018-09-14 Fondazione St Italiano Tecnologia Composti e composizioni per il trattamento della fibrosi cistica
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
MA49631A (fr) 2017-07-17 2020-05-27 Vertex Pharma Méthodes de traitement de la fibrose kystique
JP7121794B2 (ja) 2017-08-02 2022-08-18 バーテックス ファーマシューティカルズ インコーポレイテッド ピロリジン化合物を調製するためのプロセス
JP2020531511A (ja) 2017-08-24 2020-11-05 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 眼球用医薬組成物
WO2019068817A1 (en) 2017-10-05 2019-04-11 Innovative Molecules Gmbh SUBSTITUTED THIAZOLEAN ENANTIOMERS AS ANTIVIRAL COMPOUNDS
WO2019079760A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated CRYSTALLINE FORMS AND COMPOSITIONS OF CFTR MODULATORS
EP3720849A2 (en) 2017-12-08 2020-10-14 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
JP7214743B2 (ja) 2018-02-15 2023-01-30 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法
EP3774825A1 (en) 2018-04-13 2021-02-17 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
AU2019334684B2 (en) 2018-09-09 2025-03-06 Qanatpharma Ag Use of CFTR modulators for treating cerebrovascular conditions
UY38630A (es) 2019-04-03 2020-10-30 Vertex Pharma Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística
CN110117263B (zh) * 2019-06-11 2020-12-25 湖南中医药大学 2-氨基-5-酰基噻唑衍生物及其合成方法
WO2021030552A1 (en) 2019-08-14 2021-02-18 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
EP4058434A1 (en) 2019-11-12 2022-09-21 Genzyme Corporation 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity
WO2021113809A1 (en) * 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
WO2021113806A1 (en) * 2019-12-05 2021-06-10 Genzyme Corporation Arylamides and methods of use thereof
CA3179059A1 (en) * 2020-06-09 2021-12-16 Anima Biotech Inc. Collagen 1 translation inhibitors and methods of use thereof
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
IL300413A (en) 2020-08-13 2023-04-01 Vertex Pharma Crystal forms of CFTR modulators
JP7688331B2 (ja) * 2020-09-07 2025-06-04 日産化学株式会社 １，３，４－オキサジアゾール－２－アミン化合物の製造方法
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
KR20230118123A (ko) 2020-12-10 2023-08-10 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 치료 방법
CN113527225B (zh) * 2021-07-15 2022-11-18 南昌大学 一种丙烯酰噻二唑衍生物及其制备方法和应用
EP4448492B1 (en) 2021-12-17 2026-03-04 Reglagene, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
US12215102B2 (en) 2023-02-28 2025-02-04 Reglagene, Inc. Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions
US20250122171A1 (en) * 2023-09-20 2025-04-17 Deep Apple Therapeutics, Inc. Substituted Amine Compounds, Compositions and Methods of Use
KR20250121245A (ko) * 2024-02-02 2025-08-12 삼진제약주식회사 MRGPRX2 (Mas-related G-protein coupled receptor member X2) 길항제로서 신규 화합물 및 이를 포함하는 약학적 조성물

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
NZ503491A (en) * 1997-11-10 2002-08-28 Bristol Myers Squibb Co 2-substituted amino-1,3-benzothiazole derivatives useful as protein tyrosine kinase inhibitors
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
PL215901B1 (pl) * 1999-04-15 2014-02-28 Bristol Myers Squibb Co Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek
KR20020060160A (ko) * 1999-08-12 2002-07-16 파마시아 이탈리아 에스.피.에이. 3(5)-아미노-피라졸 유도체, 이의 제조 방법 및항종양제로서의 이의 용도
NZ518376A (en) * 1999-11-18 2004-01-30 Novartis Ag Pesticidal aminoheterocyclamide compounds
WO2001046165A2 (en) * 1999-12-16 2001-06-28 Novartis Ag N-heteroaryl-amides and their use as parasiticides
KR100423899B1 (ko) * 2000-05-10 2004-03-24 주식회사 엘지생명과학 세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
JP4742333B2 (ja) * 2000-11-13 2011-08-10 日本農薬株式会社 Ｎ−チアジアゾリルシクロプロパンカルボン酸アミド類およびこれを有効成分とする殺虫、殺ダニ剤
WO2002088090A2 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Pyrazole derived kinase inhibitors
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
AU2003220970A1 (en) * 2002-03-01 2003-09-16 Smithkline Beecham Corporation Diamino-pyrimidines and their use as angiogenesis inhibitors
US6900219B2 (en) * 2002-04-04 2005-05-31 Cv Therapeutics, Inc. ABCA-1 elevating compounds
TW200403058A (en) * 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
EP1558607B1 (en) * 2002-10-30 2010-05-05 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
EP1581217A4 (en) * 2002-11-01 2007-07-11 Merck & Co Inc CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF ANDROGENIC RECEPTORS
WO2004056744A1 (en) * 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
DE60336850D1 (en) * 2003-01-06 2011-06-01 Lilly Co Eli Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
US7749999B2 (en) * 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
WO2005037837A1 (ja) 2003-10-17 2005-04-28 Nippon Kayaku Kabushiki Kaisha 置換２−アミノ−[１，２，４]トリアゾロ[１，５−a]ピリミジン誘導体及びその用途
ATE473967T1 (de) * 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
US7977322B2 (en) * 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7999113B2 (en) * 2005-08-11 2011-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
CN102775396B (zh) * 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
US7671221B2 (en) * 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
CA2856037C (en) * 2005-12-28 2017-03-07 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
EP2674428B1 (en) * 2006-04-07 2016-04-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US7645789B2 (en) * 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US7754739B2 (en) * 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
SI2578571T1 (sl) * 2007-11-16 2016-01-29 Vertex Pharmaceuticals Incorporated Izokinolinski modulatorji prenašalcev z atp-vezavno kaseto
NZ720282A (en) * 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
NZ616097A (en) * 2008-03-31 2015-04-24 Vertex Pharma Pyridyl derivatives as cftr modulators

Similar Documents

Publication Publication Date Title
JP2016153424A5 (https=)
JP2018024670A5 (https=)
JP2014138100A5 (https=)
JP2019194236A5 (https=)
JP2017222697A5 (https=)
JP2011527560A5 (https=)
JP2009149903A5 (https=)
JP2010501534A5 (https=)
JP2020515557A5 (https=)
JP2017214410A5 (https=)
JP2015522045A5 (https=)
JP2014028813A5 (https=)
JP2018116258A5 (https=)
JP2019089762A5 (https=)
JP2015199738A5 (https=)
JP2013532130A5 (https=)
JP2018150298A5 (https=)
JP2014235432A5 (https=)
JP2018521020A5 (https=)
JP2018030858A5 (https=)
JP2012094862A5 (https=)
JP2019502666A5 (https=)
JP2011037885A5 (https=)
JP2018509309A5 (https=)
JP2017019744A5 (https=)